Updated 10 August 2026. Regulatory status current as of this date.
Most approved peptide medicines are legal when prescribed appropriately. But wellness and lifestyle peptides such as BPC-157, TB-500 and MOTS-c remain unapproved and unproven; the FDA’s July 2026 advisory vote did not make them approved or immediately legal to compound. UK rules depend partly…
Eli Lilly is progressing its experimental obesity and type 2 diabetes drug retatrutide into Phase 3 trials, following late-stage data showing significant weight loss and metabolic improvements.
Retatrutide belongs to a new class of drugs known as triple agonists, targeting three key metabolic pathways simultaneously. In earlier trials, the drug demonstrated weight loss outcomes exceeding…



